Product Description
A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal,Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: France | India | Slovenia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer|Bone Cancer|Hypothalamic Diseases|Prostatic Hyperplasia|Testicular Diseases|Hypothalamic Cancer|Protein Deficiency|Vascular Cancer|Hypogonadism|Skin Cancer|Pituitary Cancer|Inflammation|Prostatic Diseases|Bladder Cancer|Pregnancy Outcomes|Testicular Cancer|Hypopituitarism|Deficiency Diseases|Pituitary Diseases|Skin Diseases, Vascular|Breast Cancer
Phase 1: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FDHT - version 1, 9 March 2015 | P2 |
Terminated |
Prostate Cancer |
2018-09-15 |
2022-03-13 |
Treatments |
|
| [18F]FDHT PET in hormone naive prostate cancer | P2 |
Active, not recruiting |
Prostate Cancer|Bone Cancer |
2016-02-11 |
2022-03-13 |
Treatments |
|
| 2012-003981-42 | P2 |
Completed |
Breast Cancer |
2015-05-13 |
2025-06-14 |
Treatments |
|
| IRB00015971 | P1 |
Terminated |
Prostate Cancer |
2013-03-01 |
2019-03-19 |
||
| DHT-3 | P2 |
Completed |
Pregnancy Outcomes|Prostate Cancer|Deficiency Diseases|Hypothalamic Cancer|Testicular Cancer|Hypopituitarism|Testicular Diseases|Vascular Cancer|Prostatic Hyperplasia|Hypothalamic Diseases|Bladder Cancer|Pituitary Cancer|Skin Diseases, Vascular|Prostatic Diseases|Pituitary Diseases|Inflammation|Hypogonadism|Protein Deficiency|Skin Cancer |
2009-01-01 |
2019-03-21 |
Treatments |
|
| 03-DHT-01 | P2 |
Completed |
Hypogonadism |
2006-09-01 |
2022-08-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |